Introduction {#s1}
============

A translating ribosome stalls when it encounters the end of a non-stop mRNA, truncated during cellular stress or homeostasis, by premature transcription termination or mRNA cleavage or other mechanisms ([@bib24]; [@bib30]). The stalled ribosome contains *[p]{.ul}*eptidyl-tRNA in the *P* site, whereas the *[a]{.ul}*minoacyl-tRNA (*A*) site is unoccupied ([@bib27]). Bacteria have evolved ribosome-rescue pathways to release the nascent peptide and re-enable the stalled ribosome for translation (for a review, see ref. \[[@bib30]\]). The ArfA ([a]{.ul}lternative [r]{.ul}escue [f]{.ul}actor [A]{.ul}) pathway is essential in trans-translation-deficient cells ([@bib8]) and is thought to function as a backup mechanism for trans-translation in enterobacteria ([@bib20]; [@bib9]; [@bib51]). ArfA is a small protein (\~70 aa in most organisms), with only 47 amino acids sufficient for function, as shown for *E. coli* ArfA truncations ([@bib20]). ArfA recruits release factor RF2 to rescue stalled ribosomes ([@bib10]; [@bib53]). RF2 normally mediates translation termination at UGA or UAA stop codons by binding the stop codon and catalyzing peptidyl-tRNA hydrolysis and release of the nascent peptide ([@bib13]; [@bib37]). RF2 has remarkable specificity toward stop codons ([@bib18]) and does not function alone on truncated mRNA ([@bib10]; [@bib53]). In this work, we asked how ArfA and RF2 sense the stalled ribosome, and how ArfA aids RF2 to catalyze peptide release in the absence of a stop codon.

To better understand ribosome rescue by ArfA and RF2, we formed an *E. coli* 70S ribosome rescue complex with mRNA truncated after an AUG codon in the P site, tRNA^fMet^, ArfA and RF2, and captured images of complexes by electron cryo-microscopy (cryo-EM; see Materials and methods). Unsupervised classification of a single cryo-EM dataset ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) using FREALIGN ([@bib22]) revealed two ribosome structures with both ArfA and RF2 bound in the A site (Structures I and II; [Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Structure I contains a compact RF2 ([Figure 1A and C](#fig1){ref-type="fig"}) and is represented by \~26% of ribosome particles in the cryo-EM dataset. Structure II contains an extended RF2 ([Figure 1B and D](#fig1){ref-type="fig"}; \~18% of ribosomes). Both structures contain tRNAs in the P and E (exit) sites and adopt a non-rotated conformation ([@bib66]; [@bib34]; [@bib52]), similar to that in translation termination complexes ([@bib35]; [@bib39]; [@bib63]). High-resolution maps ([Figure 1E and F](#fig1){ref-type="fig"} and [Figure 1---figure supplements 3](#fig1s3){ref-type="fig"}--[5](#fig1s5){ref-type="fig"}) allowed de novo modeling of ArfA ([Figure 1E](#fig1){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}) and detailed structure determination of RF2 ([Figure 1E and F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}) in each ribosome structure. The molecular interactions and conformational rearrangements inferred from Structures I and II provide the structural basis for ArfA-mediated ribosome rescue, as described below.10.7554/eLife.23687.002Figure 1.3.2 Å resolution cryo-EM structures of *E. coli* 70S ribosome bound with ArfA and release factor RF2.(**A**) Structure I with RF2 in a compact conformation; (**B**) Structure II with RF2 in an extended conformation. Domains 2 and 3 and the GGQ motif of RF2 are labeled. (**C**) and (**D**) A close-up view down the mRNA tunnel, showing RF2 and ArfA in the A site of Structure I (**C**) and Structure II (**D**). The body and head domains of the 30S subunit are labeled. (**E**) Extended β-sheet formed by ArfA (red model) and RF2 (blue model). Cryo-EM map (gray mesh) is shown for Structure II at σ = 2.5. (**F**) Peptidyl-transferase center bound with the ^250^GGQ^252^ motif of RF2 in Structure II. Cryo-EM map (gray mesh) is shown at σ = 2.5 for RF2 and at σ = 4.5 for 23S ribosomal RNA and the ^74^CCA^76^ end of the P-site tRNA. The maps were sharpened by applying the B-factor of −120 Å^2^. Additional views of cryo-EM density are available in [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[5](#fig1s5){ref-type="fig"}. In all panels, the large 50S ribosomal subunit is shown in gray/light-blue; the small 30S subunit in yellow; mRNA in green; E-site tRNA in magenta; P-site tRNA in orange; ArfA in red and RF2 in blue.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.002](10.7554/eLife.23687.002)10.7554/eLife.23687.003Figure 1---figure supplement 1.Schematic of cryo-EM refinement and classification.All particles (4x stack) were initially aligned to a single model. 3D classification (10 classes) using the unbinned (1x binned) stack was used to identify the particles containing ArfA and RF2. Subsequent 3D classification using a spherical mask around the A site yielded three 'purified' classes representing Structure I, Structure II and the ribosome with a vacant A site. Additional sub-classifications (including up to eight classes) did not yield additional structures (e.g. ArfA-, RF2- or ArfA•RF2-containing classes). Light blue color for RF2 means partial occupancy of RF2. Junk classes are low-resolution classes with poorly resolved structural features that likely originate from misaligned, incomplete or damaged ribosomes.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.003](10.7554/eLife.23687.003)10.7554/eLife.23687.004Figure 1---figure supplement 2.Cryo-EM densities of Structures I and II.(**A**) and (**B**) Cryo-EM maps of 70S•ArfA•RF2 complexes were segmented and colored as in [Figure 1](#fig1){ref-type="fig"}. (**C**) and (**D**) Cryo-EM density (gray) for ArfA (red model) and RF2 (blue model) in Structures I and II. The maps were sharpened by applying the B-factor of −120 Å^2^. (**E**) Fourier shell correlation as a function of resolution for Structures I and II.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.004](10.7554/eLife.23687.004)10.7554/eLife.23687.005Figure 1---figure supplement 3.Cryo-EM densities corresponding to N- and C-terminal regions of ArfA in Structures I and II.(**A**) Superposition of ArfA in Structures I (red) and Structure II (cyan), achieved by structural alignment of the 16S ribosomal RNA. Conformations of the N-terminal region of ArfA relative to the 30S subunit differ between Structures I and II; the difference in the position of the α-helical part is shown with an arrow. (**B**) Partially resolved α-helical part at the N-terminus and the C-terminal part of ArfA in Structure I (red model) defined by density (gray mesh) at σ = 2.5. (**C**) Well-resolved α-helical part at the N-terminus and the C-terminal part of ArfA in Structure II (red model) defined by density (gray mesh) at σ = 2.5. The maps were sharpened by applying the B-factor of −120 Å^2^. A poorly defined region (with the backbone traceable at low σ = 1.0) of the C-terminal structure is colored in gray.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.005](10.7554/eLife.23687.005)10.7554/eLife.23687.006Figure 1---figure supplement 4.Cryo-EM densities corresponding to functional regions of RF2 in Structures I and II.(**A**) Compact conformation of RF2 (blue model) defined by density (gray mesh) at σ = 2.5 (except for the map around the switch loop shown at σ = 1.5). Close-up views are shown in boxes for the SPF and GGQ motifs and the switch loop (the orientations differ from that in the main panel). Gray regions are poorly defined in the map, in that the backbone is only traceable at low σ of 1.0 or lower. (**B**) Extended conformation of RF2 defined by density at σ = 2.5. Close-up views are shown in boxes for the SPF and GGQ motifs and the switch loop. The maps were sharpened by applying the B-factor of −120 Å^2^. Side chains of most residues are omitted for clarity.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.006](10.7554/eLife.23687.006)10.7554/eLife.23687.007Figure 1---figure supplement 5.Cryo-EM densities of ribosomal RNA in Structure II.(**A**) Density (gray mesh) at σ = 4.5 for 16S rRNA nucleotides forming base pairs. (**B**) Density (gray mesh) at σ = 4.5 for 23S rRNA (part of helix 86) (**C**) Densities (gray mesh) for a magnesium ion at σ = 4.5 (gold sphere) coordinated by 16S rRNA (yellow) at σ = 6.0 or 23S rRNA (gray) at σ = 6.0. The maps were sharpened by applying the B-factor of −150 Å^2^.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.007](10.7554/eLife.23687.007)10.7554/eLife.23687.008Table 1.Cryo-EM data collection and refinement statistics.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.008](10.7554/eLife.23687.008)Structure IStructure II**PDB code**5U9G5U9F**EMDB code**EMD-8522EMD-8521**Data collection**EM equipmentFEI Titan KriosFEI Titan KriosVoltage (kV)300300DetectorDE-20DE-20Pixel size (Å)1.2151.215Electron dose (e^-^/Å^2^)61 (used 30)61 (used 30)Defocus range (μm)−0.5 to −3.0−0.5 to −3.0**Reconstruction**SoftwareFrealign v9.10--9.11Frealign v9.10--9.11Number of particles used139,86196,070Final resolution (Å)3.153.15Map-sharpening *B*\
factor (Å^2^)−92.1−89.9**Model building**SoftwareCootCoot**Model composition**Non-hydrogen atoms152671152841Protein residues65616576RNA bases47294729Ligands (Zn^2+^/Mg^2+^)1/3481/360**Refinement**SoftwareRSRef and PhenixRSRef and PhenixCorrelation Coeff\
(%; Phenix)82.9080.40R-factor (RSRef)0.1870.194**Validation (proteins)**MolProbity score2.32.2Clash score, all atoms12.613.0Good rotamers (%)93.794.4Ramachandran-plot\
statistics (%)Favored (overall)88.488.2Allowed (overall)10.610.8Outlier (overall)1.01.0Favored (ArfA)86.788.9Allowed (ArfA)13.311.1Outlier (ArfA)\--Favored (RF2)86.492.5Allowed (RF2)13.67.2Outlier (RF2)-0.3R.m.s. deviationsBond length (Å)0.0060.005Bond angle (˚)0.8520.864**Validation (RNA)**Correct sugar puckers (%)99.999.9Good backbone\
conformation (%)85.285.3

Results and discussion {#s2}
======================

ArfA C-terminus occupies the mRNA tunnel to sense the stalled ribosome {#s2-1}
----------------------------------------------------------------------

Sequence alignment of several hundreds of bacterial ArfA homologs reveals conserved hydrophobic N-terminal and positively charged C-terminal regions ([Figure 2](#fig2){ref-type="fig"}). The high conservation of these regions implicates their functions in protein and RNA interactions, respectively. In Structures I and II, the conformations of the N-terminal region differ as described in the following sections, but the rest of ArfA is similar. The mid-region of ArfA (His21 to Glu30; *E. coli* numbering is used) lies in the A site ([Figure 1C and D](#fig1){ref-type="fig"}). ArfA leaves a \~12 Å gap in the codon-binding region, sufficient to accommodate one or two nucleotides of mRNA following the P-site codon but not a longer mRNA, consistent with the reduced efficiency of ArfA-mediated release on mRNAs that extend three or more nucleotides beyond the P site ([@bib53]; [@bib67]).10.7554/eLife.23687.009Figure 2.Structure and sequence of ArfA.(**A**) Close-up view of the intersubunit space and mRNA tunnel occupied by ArfA in Structure II. The color-coding is the same as in [Figure 1](#fig1){ref-type="fig"}. The head and body domains of the 30S subunit are labeled. (**B**) Sequence and structure of ArfA, shown in the same orientation as in (**A**). Sequence conservation among \~400 non-redundant bacterial ArfA homologs is shown for four ArfA regions (see Materials and methods). The color code for amino acid type in the sequence logo is the following: green -- polar, purple -- neutral, blue -- basic, red -- acidic and black -- hydrophobic residues.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.009](10.7554/eLife.23687.009)10.7554/eLife.23687.010Figure 2---figure supplement 1.Comparison of mRNA tunnel occupancies by ribosome rescue proteins ArfA, ArfB and SmpB (shown in red).(**A**) Structure of ArfA and interactions with the 30S subunit in Structure II (this work), (**B**) Structure of ArfB and interactions with the 30S subunit in the crystal structure of the 70S-bound ArfB (PDB 4V95) (**C**) Structure of SmpB and interactions with the 30S subunit in the crystal structure of the 70S-bound SmpB and tmRNA mimic (PDB 4V8Q). In all panels, the 30S subunit is shown in yellow, P-site tRNA in orange and mRNA in green. The entrance to the mRNA tunnel (at the solvent interface of the 30S subunit) is formed by proteins S3, S4 and S5, which are labeled in panel A. G530 is labeled in each panel to show the location of the decoding center.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.010](10.7554/eLife.23687.010)10.7554/eLife.23687.011Figure 2---figure supplement 2.Putative α-helical structure of the C-terminal region of ArfA at the entry of the mRNA tunnel (near protein S5) in Structures I and II (Structure II is shown).The view is similar to that shown in [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}. The α-helix at the C-terminal tail of ArfA is predicted by ROBETTA and I-TASSER. The putative structural model (aa \~47--55) is colored in gray and defined by density (gray mesh) at σ = 2.0. The map was sharpened by applying the B-factor of −120 Å^2^. The 30S subunit is shown in yellow; the well-ordered part of ArfA (up to aa 46) is shown in red.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.011](10.7554/eLife.23687.011)10.7554/eLife.23687.012Figure 2---figure supplement 3.Structure of the N-terminal tail of ArfA near the decoding center in Structure II.The N-terminus of ArfA (red) is positioned next to A520 of helix 18 of 16S rRNA (within \~10 Å) and contacts S12. Polar residues Thr7 and Lys8 interact with h44 of 16S rRNA (at A1410) and h69 of 23S RNA (at C1914), respectively. The 30S subunit is shown in yellow, 50S in light blue, RF2 in blue. The switch loop of RF2 is highlighted in yellow-green.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.012](10.7554/eLife.23687.012)

The C-terminal region of ArfA occupies the mRNA tunnel between the head and body of the 30S subunit ([Figure 2---figure supplements 1A](#fig2s1){ref-type="fig"} and [2](#fig2s2){ref-type="fig"}), as suggested by previous hydroxyl-radical probing studies ([@bib38]). The mRNA tunnel is primarily formed by the negatively charged 16S rRNA backbone. ArfA is stabilized by electrostatic interactions, as positively charged amino acids comprise nearly half of the ArfA residues within the mRNA tunnel (aa 31--48; [Figure 2B](#fig2){ref-type="fig"}). ArfA residues Lys44 to Arg48 approach the mRNA tunnel entry at the solvent side of the 30S subunit, formed by 16S rRNA and proteins S3, S4 and S5 ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Consistent with ArfA structure prediction ([@bib31]; [@bib65]), the tail of ArfA appears to form a short α-helix (aa \~50--55) next to S5; however, the resolution of the map is not sufficient to build an unambiguous structural model ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). This suggests conformational disorder of the C-terminus at the entrance to the mRNA tunnel. Our structures are consistent with biochemical studies ([@bib9]), which showed that ArfA is functional with a C-terminal truncation at Asn47, but further shortening inactivates ArfA. In particular, truncations following Met40---removing at least five basic amino acids that bind in the tunnel---abrogate ArfA-mediated release by reducing ArfA affinity for the 70S ribosome ([@bib9]).

We compared ArfA with proteins ArfB (also known as YaeJ; \[[@bib19]\]) and SmpB ([@bib44]; [@bib46]), which mediate alternative rescue pathways (reviewed in \[[@bib30]\]). In ArfB-mediated release and SmpB-mediated trans-translation, the proteins sense the stalled ribosomes by occupying the mRNA tunnel ([@bib19]; [@bib44]). Consistent with sequence divergence among the C-termini of ArfA, ArfB, and SmpB, however, each interacts with the mRNA tunnel differently. ArfB performs peptide release when its C-terminus forms a long α-helix in the tunnel ([@bib19]). SmpB bound with tmRNA in preparation for trans-translation, forms a shorter α-helix, well-resolved near the mRNA entry at the 30S solvent surface ([@bib44]). SmpB is similar to ArfA in that both proteins are sensitive to the mRNA occupancy of the A site ([@bib28]; [@bib53]; [@bib67]), whereas ArfB can function on stalled ribosomes with either the vacant or occupied A site ([@bib23]). Diverged sequences, structures and binding modes of these proteins likely reflect distinct affinities and sensitivities to stress conditions, in keeping with their roles in mediating distinct ribosome rescue pathways ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

ArfA N-terminus is disordered in the presence of a compact (inactive) RF2 conformation {#s2-2}
--------------------------------------------------------------------------------------

In Structure I, only the central and C-terminal parts of ArfA are visible, indicating that the N-terminal region (aa 2--16) is disordered. RF2 adopts a compact conformation ([Figure 3A](#fig3){ref-type="fig"}) similar to that of free (ribosome-unbound) RF2 observed in crystal structures ([Figure 3B](#fig3){ref-type="fig"}) ([@bib60]; [@bib69]). By contrast, in canonical termination complexes formed on stop codons, release factors have only been observed in an extended (open) conformation ([@bib35]; [@bib63]). During translation termination, codon-recognition determinants in domain 2 (including the conserved ^205^SPF^207^ motif) of RF2 bind the stop codon in the A site of the 30S subunit. Helix α7 of domain 3 bridges the ribosomal subunits, placing the catalytic GGQ motif of domain 3 within the peptidyl-transferase center of the 50S subunit ([@bib35]; [@bib63]). In the ArfA-bound Structure I, however, helix α7 packs on the β-sheet of domain 2 near the 30S subunit ([Figure 3A and B](#fig3){ref-type="fig"}). In this compact conformation, the loop that contains the ^250^GGQ^252^ motif of RF2 lies to the side of the β-sheet (near aa 165--168) of domain 2, facing the anticodon-stem loop and the D stem of the P-site tRNA. As such, the GGQ motif is roughly 70 Å away from its catalytically engaged position within the peptidyl-transferase center ([Figure 3C and D](#fig3){ref-type="fig"}). Poor resolution of the catalytic GGQ residues ([Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}) at the tip of the loop suggests local structural flexibility, similar to that seen in crystal structures of free release factors ([@bib60]; [@bib54]; [@bib69]).10.7554/eLife.23687.013Figure 3.RF2 adopts two distinct conformations in Structures I and II.(**A**) The P and A sites of Structure I. ArfA is shown in red; RF2 in blue; mRNA in green; P-tRNA in orange; 30S subunit in yellow; and 50S subunit in light blue. (**B**) Superposition of RF2 from Structure I (blue) with the crystal structure of free (ribosome-unbound) *E. coli* RF2 (PDB 1GQE) (pink). Relative positions of the codon-recognition superdomain (domains 2 and 4) and catalytic domain 3 are nearly identical. The positions of domain 1 differ; this domain in both Structures I and II interacts with the L11 stalk at the 50S subunit shown in panels (**A**), (**C**) and (**F**). (**C**) The P and A sites of Structure II. The color coding is as in panel (**A**). (**D**) Superposition of extended RF2 in Structure II (blue) with *Thermus thermophilus* RF2 in the canonical termination complex formed on the UAA stop codon (PDB 4V67) (pink). The superposition was performed by structural alignment of 16S ribosomal RNAs. RF2 adopts similar conformations but domains 2 and 3 are positioned slightly differently with respect to the 30S subunit in the rescue complex II and in the termination complex (see also [Figure 4](#fig4){ref-type="fig"}). (**E**) Superposition of RF2 in Structures I (blue) and II (cyan), achieved by structural alignment of the 16S ribosomal RNAs. Conformations of RF2 and positions relative to the 30S subunit differ between Structures I and II, as RF2 in Structure II binds deeper in the A site; differences in positions of RF2 regions are labeled with arrows. (**F**) Different positions of the L11 stalk, which interacts with domain 1 of RF2, in Structures I (light blue) and II (cyan), suggesting movement of the stalk together with domain 1 (**E**) upon RF2 activation. The view is similar to that shown in panels **A**, **C** and **E**. In panels (**B**), (**D**) and (**E**), the Arabic numerals label the domains of RF2.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.013](10.7554/eLife.23687.013)10.7554/eLife.23687.014Figure 4.Positions of the codon-recognition domain (blue) and switch loop (yellow-green) of RF2 in Structures I and II (this work) and in the translation termination complex formed on the UAA stop codon ([@bib35]).(**A--C**) Detailed view of the decoding center of Structure I (**A**), Structure II (**B**), and canonical termination complex formed on the UAA stop codon (**C**). (**D--F**) 90-degree rotated views (relative to those shown in panels A--C) of the decoding center in Structure I (**D**), Structure II (**E**) and the UAA-containing termination complex (**F**). The switch loop of RF2, which carries the conserved Trp319, adopts different positions in these three structures. Key structural features and residues of ArfA, RF2, mRNA stop codon and the ribosomal decoding center are labeled. ArfA is shown in red; RF2 in blue (RF2 switch loop in yellow-green); mRNA in green; 30S nucleotides in yellow; and 50S nucleotides in light blue.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.014](10.7554/eLife.23687.014)

The codon-recognition domain 2 of RF2 is positioned differently from that in canonical termination complexes. The domain is withdrawn from the A site, such that the SPF motif and other codon-recognition residues lie \~5 Å away from their positions in termination complexes bound to a stop codon ([Figure 4](#fig4){ref-type="fig"} and [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}). This position results from the mid-region of ArfA being sandwiched between domain 2 of RF2 and the decoding center. Here, the backbone of ArfA residues 25--29 binds to RF2 residues 213--217 within the β-sheet of domain 2 ([Figure 1E](#fig1){ref-type="fig"}), forming an extended β-sheet platform ([Figure 4A and D](#fig4){ref-type="fig"}). The conformation of the decoding center in Structure I differs from that in canonical termination complexes. In 70S termination complexes, the decoding center interacts with the switch loop of RF2 (aa 315--323), which bridges the codon-recognition and catalytic domains ([@bib35]; [@bib63]). A1492 bulges from helix 44 (h44) of 16S rRNA and stacks on conserved Trp319 of the switch loop ([Figure 4C](#fig4){ref-type="fig"}), stabilizing the extended conformation of RF2 on the ribosome ([Figure 4F](#fig4){ref-type="fig"}) ([@bib35]; [@bib63]). In Structure I, however, A1492 and A1493 lie inside h44 and are sandwiched between Pro23 of ArfA and A1913 of helix 69 of 23S rRNA ([Figure 4A](#fig4){ref-type="fig"}). The RF2 switch loop is poorly ordered. Putative density suggests that Trp319 is placed \>10 Å away from its position in the termination complex and does not contact the decoding-center nucleotides ([Figure 4D](#fig4){ref-type="fig"} and [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}).

Taken together, Structure I describes a 70S rescue complex in which ArfA stabilizes a compact form of RF2 resembling that of free RF2. The remote position of RF2's catalytic GGQ motif---away from the peptidyl-transferase center---indicates that Structure I represents an inactive form of the 70S rescue complex.

The ordering of the ArfA N-terminus is coupled with an extended (active) RF2 conformation {#s2-3}
-----------------------------------------------------------------------------------------

Structure II features an extended conformation of RF2 ([Figures 1B](#fig1){ref-type="fig"}, [3C and D](#fig3){ref-type="fig"}), stabilized by interactions with the ordered N-terminal region of ArfA ([Figures 2](#fig2){ref-type="fig"}, [4B and E](#fig4){ref-type="fig"}). The N-terminus of ArfA forms a minidomain, which packs between helix 69 of 23S rRNA, the β-sheet of domain 2, and extended helix α7 of RF2 ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). The tip of the ArfA minidomain (at aa 12--13) protrudes from the decoding center toward the 50S subunit, whereas the N-terminus folds back toward the decoding center, consistent with recent hydroxyl-radical probing studies ([@bib38]). Here, Thr7 and Lys8 bind h44 (at A1410) of 16S rRNA and the N-terminal amino acids bind the β-sheet of S12 ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

A hydrophobic patch in the N-terminal minidomain of ArfA ([Figure 2B](#fig2){ref-type="fig"}) --- formed by Leu19, Leu24, and Phe25---binds RF2 at Trp319 of the rearranged switch loop ([Figure 4B and E](#fig4){ref-type="fig"} and [Figure 1---figure supplement 4B](#fig1s4){ref-type="fig"}). These interactions explain the strict dependence of ArfA on RF2, rather than on the second release factor RF1 ([@bib10]; [@bib53]), whose switch loop is diverged from that of RF2 and lacks tryptophan ([@bib36]). The hydrophobic patch in the N-terminal minidomain also binds RF2 at Val198 and Phe217 of the β-sheet of the codon-recognition domain 2 ([Figure 4B and E](#fig4){ref-type="fig"} and [Figure 1---figure supplement 4B](#fig1s4){ref-type="fig"}). In this configuration, the codon-recognition domain of RF2 partially settles into the decoding center, but remains \~3 Å from its position in canonical termination complexes bound to a stop codon. As in Structure I, the SPF motif remains unbound to the ribosome or ArfA. This observation explains why mutation of SPF motif residues---critical for stop-codon recognition---do not disrupt ArfA-mediated peptide release ([@bib10]).

The position of the ArfA N-terminal minidomain between RF2's domain 2 and helix α7 of domain 3 results in docking of domain 3 into the peptidyl-transferase center ([Figures 1](#fig1){ref-type="fig"}, [3C and D](#fig3){ref-type="fig"}). The opening of domain 3 is accompanied by movement of domain 1 of RF2 ([Figure 3E](#fig3){ref-type="fig"}), which binds the L11 stalk and shifts the L11 stalk by \~7 Å toward the A site, relative to that in Structure I ([Figure 3F](#fig3){ref-type="fig"}). The coordinated shift of L11 and domain 1 likely contribute to the movement of domain 3 toward the PTC, echoing the involvement of the L11 stalk in canonical termination by RF2 ([@bib64]; [@bib50]). The catalytic GGQ motif of domain 3 binds in the peptidyl-transferase center with the catalytic backbone amide of Gln252 ([@bib35]; [@bib49]) proximal to the ribose of the terminal A76 of P-site tRNA ([Figure 1F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 4B](#fig1s4){ref-type="fig"}). The conformation of the peptidyl-transferase center is nearly identical to that seen in canonical translation termination complexes ([@bib35]; [@bib63]). Structure II therefore represents an activated state of the ArfA•RF2-bound ribosome rescue complex.

Structures I and II are in agreement with previous biochemical and mutagenesis studies, as we have described above ([@bib8], [@bib10]; [@bib53]; [@bib38]; [@bib67]). An ArfA-inactivating mutation has been identified ([@bib8]). Mutation of Ala18 of the N-terminal ArfA minidomain to threonine prevents ArfA-mediated peptide release without disrupting RF2 binding ([@bib53]). In Structure II, Ala18 lies in the hydrophobic core of the N-terminal fold, tightly packed between the nucleobase of C1914 of h69 and Ile11 of ArfA ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). The substitution to the larger threonine residue is likely incompatible with the ordered N-terminal fold of ArfA and the extended conformation of RF2. The mutation should, however, be compatible with an inactive ribosome rescue complex (Structure I), consistent with RF2 binding and the lack of catalytic activity.

Structural mechanism of ribosome rescue by ArfA and RF2 {#s2-4}
-------------------------------------------------------

During ribosome rescue, the release of the nascent peptide should strictly coordinate with the recognition of a vacant mRNA tunnel. Our cryo-EM analysis indicates that ribosomes formed on a truncated mRNA in the presence of ArfA and RF2 adopt at least three states, including Structures I, II and the ribosome with a vacant A site ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). These states suggest a structure-based model for stepwise release of nascent peptides from stalled ribosomes during ArfA-mediated ribosome rescue ([Figure 5](#fig5){ref-type="fig"}), summarized as an animation ([Video 1](#media1){ref-type="other"}, also available at <http://labs.umassmed.edu/korostelevlab/movarfa.gif>).10.7554/eLife.23687.015Figure 5.Mechanism of ArfA-mediated rescue of ribosomes stalled on truncated mRNA.(**A--B**). ArfA senses the stalled ribosome by binding its C-terminal portion in the vacant mRNA tunnel, recruiting RF2 in an inactive conformation (as in Structure I). (**C**) Folding of the N-terminal minidomain of ArfA is coupled with the opening of RF2, placing the GGQ motif into the peptidyl-transferase center (as in Structure II) and catalyzing peptidyl-tRNA hydrolysis. (**D**) Following peptide release, ArfA and RF2 (likely in a compact conformation) depart, preparing the ribosome for recycling.**DOI:** [http://dx.doi.org/10.7554/eLife.23687.015](10.7554/eLife.23687.015)Video 1.An animation showing structural transitions during ArfA-mediated ribosome rescue.Four scenes are shown: (1) A view of the complete 70S complex, as in [Figure 1A and B](#fig1){ref-type="fig"}. The stalled ribosome with a truncated mRNA and a vacant A site, identified in our cryo-EM sample ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) is followed by Structure I and Structure II. (2) The opening of RF2, from Structure I to II, coupled with the movement of the L11 stalk. The transition between Structure I and Structure II was generated using the UCSF Chimera 'Morph Conformations' tool. (3) A close-up view of the decoding center, showing the rearrangements of ribosomal nucleotides, ArfA and RF2, coupled with the opening of domain 3 of RF2. (4) A proposed mechanism of ribosome rescue by ArfA and RF2, schematically shown in [Figure 5](#fig5){ref-type="fig"}. The animation is also available at <http://labs.umassmed.edu/korostelevlab/movarfa.gif>**DOI:** [http://dx.doi.org/10.7554/eLife.23687.016](10.7554/eLife.23687.016)10.7554/eLife.23687.016

In the absence of an A-site codon, peptidyl-tRNA-bound ribosomes cannot bind aminoacyl-tRNA ([Figure 5A](#fig5){ref-type="fig"}). They are recognized by ArfA, which binds the empty mRNA tunnel and recruits a compact (inactive) conformation of RF2 ([Figure 5B](#fig5){ref-type="fig"}). Biochemical studies showed that ArfA can bind the ribosome without RF2 ([@bib38]), suggesting that ArfA precedes RF2. We do not observe ribosomes bound with ArfA alone. This indicates that ArfA has a substantially higher affinity in the presence of RF2 and predominantly binds as a complex with RF2. Additional biochemical studies are required to elucidate this step. The initial rescue complex (Structure I) then samples an extended (active) conformation of RF2 coupled to ordering of the N-terminal minidomain of ArfA at the ribosomal decoding center (Structure II; [Figure 5C](#fig5){ref-type="fig"}). Although such structural rearrangement of release factors RF1 and RF2 has not been directly observed during canonical termination, it has been suggested based on structural comparisons ([@bib47]; [@bib39]) and biochemical studies that revealed dynamic behaviors of domain 3 and the switch loop ([@bib25]; [@bib59]). A low-resolution small-angle X-ray scattering study proposed a predominant extended conformation of free *E. coli* RF1 ([@bib61]). However, subsequent characterization of *E. coli* and *Thermus thermophilus* RF2 ([@bib69]) and *E. coli* RF1 ([@bib59]) demonstrated predominance of the closed form in solution, consistent with crystal structures of RF2 and RF1 ([@bib60]; [@bib54]; [@bib69]). The tmFRET study that followed changes in inter-domain distances in RF1, found that the pre-termination ribosome initially interacts with a closed form of RF1 and induces a large-scale rearrangement ([@bib59]). The opening of a release factor is therefore a plausible conserved mechanism to separate the 'decoding' and 'catalytic' functions of release factors.

In the 70S•ArfA•RF2 complex, the opening of RF2 places the GGQ motif into the peptidyl-transferase center (Structure II), where it catalyzes peptidyl-tRNA hydrolysis, releasing the nascent peptide from the ribosome ([Figure 5C](#fig5){ref-type="fig"}). Dissociation of ArfA and RF2, possibly through the inactive Structure I state ([Figure 5D](#fig5){ref-type="fig"}), results in ribosomes with a vacant A site and deacylated tRNA in the P site, enabling subsequent recycling of the ribosome.

After submission of this manuscript, several other structures of 70S•ArfA•RF2 complexes with RF2 in the extended conformation were reported ([@bib29]; [@bib26]; [@bib41]; [@bib68]). Structure I, however, was not found in these studies. A compact conformation of RF2, similar to that in Structure I, was observed in the presence of a heterologous ArfA•RF2 system or the ArfA A18T mutant ([@bib29]). The observation of both the compact and extended RF2 conformations in a single dataset in our work could be the result of different conditions of complex preparation and/or data processing and classification (see Materials and methods). In summary, the reported structures closely agree with our findings and are consistent with the proposed mechanism of ribosome rescue.

The mechanism of ArfA-mediated ribosome rescue is remarkably different from canonical translation termination, wherein RF2 accurately defines the lengths of cellular proteins by direct recognition of stop codons in the A site ([@bib35]; [@bib63]). While ArfA converts RF2 into a stop-codon-independent release factor, our structures show that: (i) ArfA does not mimic a stop codon; (ii) the conserved codon-recognition elements of RF2---including the SPF motif---are not required ([@bib10]); and (iii) instead of interacting directly with RF2, the ribosomal decoding center stabilizes ArfA, which in turn stabilizes an active RF2 conformation. Thus, bacteria have evolved an intricate stress-response mechanism in which a small protein with specific affinity to the stalled ribosome re-purposes a release factor. The ArfA-mediated ribosome rescue highlights an impressive ability of living organisms to co-opt existing cellular mechanisms for different and sometimes mutually exclusive purposes.

Materials and methods {#s3}
=====================

Preparation of ArfA and RF2 {#s3-1}
---------------------------

The gene encoding *E. coli* ArfA (ASKA Clone(-) library, National BioResource Project, NIG, Japan) was subcloned into pET24b+ (Novagen) kanamycin resistance vector using the primer set CCCG[CATATG]{.ul}CATCACCATCACCATCACATGAGTCGATATCAGCATACTAAAGGGC/CCCG[GGATCC]{.ul}GTGATTTACTTTCTTGCCAC containing the NdeI/BamHI restriction sites (underlined) and transformed into an *E. coli* BLR/DE3 strain. The resulting ArfA protein is 60 amino acids long and is N-terminally His~6~-tagged. DNA sequencing confirmed the native sequence of the ArfA gene. Cells containing the pET24b+ plasmid were cultured in Luria-Bertani (LB) medium with 50 µg mL^−1^ kanamycin at 37°C until the OD~600~ reached 0.7--0.8. Expression of ArfA was induced by 1 mM IPTG (Gold Biotechnology Inc., USA), followed by cell growth for 9 hr at 16°C. The cells were harvested, washed and resuspended in buffer A (50 mM Tris-HCl (pH 7.5), 150 mM KCl, 10 mM imidazole, 6 mM β-mercaptoethanol (βME) and protease inhibitor (complete Mini, EDTA-free protease inhibitor tablets, Sigma Aldrich, USA). The cells were disrupted with a microfluidizer (Microfluidics, USA), and the soluble fraction was collected by centrifugation at 18,000 rpm for 20 min and filtered through a 0.22 µm pore size sterile filter (CELLTREAT Scientific Products, USA).

ArfA was purified in three steps. The purity of the protein after each step was verified by 12% SDS-PAGE stained with Coomassie Brilliant Blue R 250 (Sigma-Aldrich). First, affinity chromatography with Ni-NTA column (Nickel-nitrilotriacetic acid, 5 ml HisTrap, GE Healthcare) was performed using FPLC (Äkta explorer, GE Healthcare). The cytoplasmic fraction was loaded onto the column equilibrated with buffer A and washed with the same buffer. ArfA was eluted with a linear gradient of buffer B (buffer A with 0.5 M imidazole). Fractions containing ArfA were pooled and dialyzed against buffer C (buffer A without imidazole). The protein then was purified by ion-exchange chromatography (5 ml HiTrap FF Q-column, GE Healthcare; FPLC). The column was equilibrated and washed with Buffer C, the protein was loaded in Buffer C and eluted with linear gradient of Buffer D (Buffer C with 1 M KCl). Finally, the protein was dialyzed against 50 mM Tris-HCl buffer (pH 7.5), 150 mM KCl, 6 mM βME and protease inhibitor (complete Mini, EDTA-free protease inhibitor tablets, Sigma Aldrich, USA) and purified using size-exclusion chromatography (Hiload 16/60 Superdex 75 pg column, GE Healthcare). The fractions of the protein were pulled, buffer exchanged (25 mM Tris-HCl (pH 7.0), 50 mM K(CH~3~COO), 10 mM Mg(CH~3~COO)~2~, 10 mM NH~4~(CH~3~COO) and 6 mM βME) and concentrated with an ultrafiltration unit using a 3 kDa cutoff membrane (Millipore). The concentrated protein was flash-frozen in liquid nitrogen and stored at −80°C.

N-terminally His~6~-tagged RF2 (*E. coli* K12 strain) was purified as described ([@bib35]; [@bib39]).

Preparation of the 70S rescue complex bound with ArfA•RF2 {#s3-2}
---------------------------------------------------------

70S ribosomes were prepared from *E. coli* (MRE600) as described ([@bib42], [@bib43]), and stored in the ribosome-storage buffer (20 mM Tris-HCl (pH 7.0), 100 mM NH~4~Cl, 12.5 mM MgCl~2~, 0.5 mM EDTA, 6 mM βME) at −80°C. Ribosomal 30S and 50S subunits were purified using sucrose gradient (10--35%) in a ribosome-dissociation buffer (20 mM Tris-HCl (pH 7.0), 300 mM NH~4~Cl, 1.5 mM MgCl~2~, 0.5 mM EDTA, 6 mM βME). The fractions containing 30S and 50S subunits were collected separately, concentrated and stored in the ribosome-storage buffer at −80°C. *E. coli* tRNA^fMet^ was purchased from Chemical Block. RNA, containing the Shine-Dalgarno sequence and a linker to place the AUG codon in the P site (GGC AAG GAG GUA AAA [AUG]{.ul}) was synthesized by IDT.

The 70S•mRNA•tRNA^fMet^•ArfA•RF2 complex was prepared by reconstitution in vitro. 2 µM 30S subunit (all concentrations are specified for the final solution) were pre-activated at 42°C for 5 min in the ribosome-reconstitution buffer (20 mM Tris-HCl (pH 7.0), 100 mM NH~4~Cl, 20 mM MgCl~2~, 0.5 mM EDTA, 6 mM βME). After pre-activation, 1.8 µM 50S subunit with 24 µM mRNA and 12 µM tRNA^fMet^ were added to the 30S solution and incubated for 15 min at 37°C. ArfA and RF2 were then added at 16 µM each and the solution was incubated for 15 min at 37°C and cooled down to room temperature. The solution was aliquoted, flash-frozen in liquid nitrogen and stored at −80°C.

Activity of ArfA and RF2 {#s3-3}
------------------------

Activity of ArfA and RF2 in the ArfA-mediated rescue was tested using \[^35^S\]-formylmethionine release assay, essentially as we described previously ([@bib56]). The pre-termination complex was formed using *E. coli* 70S ribosomes, \[^35^S\]-labeled fMet-tRNA^fMet^ (^35^S-labeled methionine from Perkin Elmer) and truncated mRNA described above. Consistent with published data ([@bib10]; [@bib53]), neither ArfA nor RF2 alone induced release of \[S^35^\]-fMet from the pre-termination complex. Similarly, a combination of ArfA and RF1 did not result in \[S^35^\]-fMet release, consistent with the requirement for RF2. By contrast, efficient release was observed in 10 min after addition of ArfA and RF2 in combination, consistent with published data ([@bib67]). The time of the cryo-EM sample incubation prior to freezing (15 min, as described in the previous section) was therefore sufficient for achieving equilibrium and peptide release, suggesting that the cryo-EM structures represent interconverting equilibrium states.

The release activity was tested as follows. 70S ribosome complex was formed by incubation of 0.7 μM (all concentrations are given for the final complex) of the 30S subunit at 42°C for 5 min, followed by addition of 0.7 μM of the 50S subunit, 3.5 μM truncated mRNA and incubation at 37°C for 20 min (20 mM Tris acetate (pH 6.5), 100 mM ammonium acetate and 20 mM magnesium acetate). The mixture was cooled to room temperature. 1 μM RF2, 10 μM ArfA and 150 nM \[^35^S\]-fMet-tRNA^fMet^ were added to the solution to form the rescue complex (ArfA or RF2 were also tested separately in independent experiments). 10 μl of the rescue complex were immediately quenched in 0.1 M HCl to represent a zero-time point. 10 μl aliquots collected after 10 min and 1 hr were quenched in 30 μl of 0.1 M HCl. \[^35^S\]-fMet-tRNA^fMet^ was extracted with 700 μl of ethylacetate; 600 μl of the extract were mixed with 3.5 ml of a scintillation cocktail (Econo-Safe). Samples were quantified using a scintillation counter (Beckman).

Cryo-EM and image processing {#s3-4}
----------------------------

Holey-carbon grids (C-flat 2/2) were exposed to a 75% argon/25% oxygen plasma for 20 s using a Solarus 950 plasma cleaning system. The forward RF target was set to 7w. Before being applied to the grids, the 70S•mRNA•tRNA^fMet^•ArfA•RF2 complex was diluted in the ribosome-reconstitution buffer supplemented with ArfA and RF2 to the following final concentrations: \~0.45 µM 70S, 6 µM mRNA, 3 µM tRNA^fMet^, 10 µM ArfA and 10 µM RF2. 2 μl of the 70S•mRNA•tRNA^fMet^•ArfA•RF2 complex was applied to the grids. The grids were blotted for 5 s at blotting power 8 at 4°C and \~95% humidity and plunged into liquid ethane using an FEI Vitrobot MK4. The grids were stored in liquid nitrogen.

A dataset of 539,311 particles was collected as follows. 3760 movies were collected using Leginon ([@bib55]) on an FEI Krios microscope operating at 300 kV equipped with a DE-20 Camera System (Direct Electron, LP, San Diego, CA) with −0.5 to −3.0 μm defocus. Each exposure was acquired with continuous frame streaming at 32 frames per second (fps) with various exposure lengths (38, 40, 54, 57 and 72 frames per movie) yielding a total dose of 61 e^−^/Å^2^. The nominal magnification was 29,000 and the calibrated pixel size at the specimen level was 1.215 Å. The frames for each movie were processed using DE_process_frames script (in EMAN2 \[[@bib58]\]) which is available from Direct Electron at <http://www.directelectron.com/scripts>. The movies were motion-corrected and frame averages were calculated using the first half of each movie (data up to a dose of \~30 e^−^/Å^2^) and excluding the first two frames, after multiplication with the corresponding gain reference. CTFFIND4 ([@bib48]) was used to determine defocus values for each resulting frame average. 503 movies with large drift, low signal, heavy ice contamination, or very thin ice were excluded from further analysis after inspection of the averages and the power spectra computed by CTFFIND4. Particles were semi-automatically picked from full-sized images in EMAN2 using \~50 particles picked manually to serve as a reference. 320 × 320 pixel boxes with particles were extracted from images and normalized. The stack and FREALIGN parameter file were assembled in EMAN2. To speed up data processing, a 4x-binned image stack was prepared using EMAN2.

Data classification is summarized in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. FREALIGN v9 (versions 9.10--9.11) was used for all steps of refinement and reconstruction ([@bib22]). The 4x-binned image stack (539,311 particles) was initially aligned to a ribosome reference (PDB 4V4A) ([@bib62]) using 3 cycles of mode 4 (search and extend) alignment including data in the resolution range from 300 Å to 30 Å until the convergence of the average score. Subsequently, the 4x binned stack was aligned against the common reference resulting from the previous step, using mode 1 (refine) in the resolution ranges 300--18 Å and 300--12 Å (for both ranges, 3 cycles of mode one were run). In the following steps, the 4x binned stack was replaced by the unbinned (full-resolution) image stack, which was successively aligned against the common reference using mode 1 (refine), including gradually increasing resolution limits (increments of 1 Å, five cycles per each resolution limit) up to 6 Å. The resolution of the resulting common reference was 3.29 Å (Fourier Shell Correlation (FSC) = 0.143). Subsequently, the refined parameters were used for classification of the unbinned stack into 10 classes in 30 cycles using the resolution range of 300--6 Å. This classification revealed seven high-resolution classes and three low-resolution (junk) classes ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The particles assigned to the high-resolution classes that contained RF2 and ArfA were extracted from the unbinned stack (with \>50% occupancy and scores \>0) using merge_classes.exe (part of the FREALIGN distribution), resulting in a stack containing 320,895 particles. Classification of this stack was performed for 30 cycles using a focused spherical mask around the A site (55 Å radius, as implemented in FREALIGN). This classification yielded three high-resolution classes, two of which contained both ArfA and RF2 (Structures I and II) and one with a vacant mRNA tunnel and A site. Using more classes (up to 8) did not yield additional structures (e.g. containing ArfA alone, RF2 alone or additional ArfA•RF2 conformations). For the classes of interest (Structures I and II), particles with \>50% occupancy and scores \>0 were extracted from the unbinned stack. Refinement to 6 Å resolution using mode 1 (five cycles) resulted in \~3.15 Å maps (FSC = 0.143). The maps were sharpened using automatically calculated B-factors (approximately −90 Å^2^) in bfactor.exe (part of the FREALIGN distribution) and used for model building and structure refinements. B-factors of −120 or −150 Å^2^ were also used to interpret high-resolution details in the ribosome core regions. FSC curves were calculated by FREALIGN for even and odd particle half-sets.

Following the submission of our manuscript, several groups reported 70S•ArfA•RF2 cryo-EM structures ([@bib29]; [@bib26]; [@bib41]; [@bib68]), but each dataset contained a single ArfA•RF2 conformation (similar to our Structure I and Structure II), unlike our dataset, which contained both ArfA•RF2 states. We hypothesize that this difference may be due to several factors. First, different dataset sizes and processing strategies may have influenced the identification of particle classes. Most notably, we use FREALIGN in all our work for particle alignment and classification, consistently yielding multiple states ([@bib57]; [@bib32]; [@bib1]; [@bib40]). In some cases, this contrasted the results from other groups that reported only single states. Most recently, we reported several globally different 70S•RelA states from a single sample ([@bib40]) while work on similar (but not identical) 70S•RelA complexes using different data processing approaches yielded only a single state ([@bib4]; [@bib6]). However, clarification of the role of FREALIGN in our consistent discovery of multiple structures requires further testing, including reprocessing of datasets from different groups with different software. Second, different buffer conditions, strategies of complex formation (e.g. the use of individual ribosomal subunits in our work) and constructs (e.g. ribosome, RF2 or ArfA strains) may have led to different equilibria between Structure I and Structure II. The presence of the His~6~-tag on ArfA in our work may have led to stabilization of Structure I. In the absence of density for His~6~ in our maps, however, we cannot explain how it may have stabilized the structure.

Model building and refinement {#s3-5}
-----------------------------

Recently reported cryo-EM structure of *E. coli* 70S•RelA•A/R-tRNA^Phe^ complex ([@bib40]), excluding RelA and tRNA^Phe^, was used as a starting model for structure refinement. The structure of compact RF2 (Structure I) was built using the crystal structure of free RF2 (PDB 1GQE) ([@bib60]) as a starting model. The extended form of RF2 (Structure II) was created by homology modeling from *Thermus thermophilus* RF2 within a 70S termination complex ([@bib35]) using SWISS-PROT ([@bib5]). ArfA was modeled de novo in Coot (RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)) ([@bib17]), using an initial structure predicted by ROBETTA ([@bib31]). The secondary structure in our resulting model of AfrA is consistent with those predicted by ROBETTA and I-TASSER (RRID:[SCR_014627](https://scicrunch.org/resolver/SCR_014627)) ([@bib65]). Initial protein and ribosome domain fitting into cryo-EM maps was performed using Chimera (RRID:[SCR_004097](https://scicrunch.org/resolver/SCR_004097)) ([@bib45]), followed by manual modeling using Pymol (RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)) ([@bib15]) and Coot. The linkers between the domains and parts of the domains that were not well defined in the cryo-EM maps (e.g. loops of RF2 in Structure I, shown in [Figure 1---figure supplement 4A](#fig1s4){ref-type="fig"}) were modeled as protein or RNA backbone.

Structures I and II were refined by real-space simulated-annealing refinement using atomic electron scattering factors ([@bib21]) in RSRef ([@bib11]; [@bib33]) as described ([@bib57]). Secondary-structure restraints, comprising hydrogen-bonding restraints for ribosomal proteins and base-pairing restraints for RNA molecules, were employed as described ([@bib35]). Refinement parameters, such as the relative weighting of stereochemical restraints and experimental energy term, were optimized to produce the stereochemically optimal models that closely agree with the corresponding maps. In the final stage, the structures were refined using phenix.real_space_refine (RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)) ([@bib2]), followed by a round of refinement in RSRef applying harmonic restraints to preserve protein backbone geometry. Ions were modeled as Mg^2+^, filling the difference-map peaks using CNS ([@bib7]). To this end, the maps were converted to structure factors using phenix.map_to_structure_factors ([@bib2]). The refined structural models closely agree with the corresponding maps, as indicated by high correlation coefficients of \>0.8 and low real-space R-factors of 0.19 for Structures I and II. The resulting models have excellent stereochemical parameters, characterized by low deviation from ideal bond lengths and angles, low number of protein-backbone outliers (no outliers in ArfA) and other robust structure-quality statistics, as shown in [Table 1](#tbl1){ref-type="table"}. Structure quality was validated using MolProbity (RRID:[SCR_014226](https://scicrunch.org/resolver/SCR_014226)) ([@bib12]).

Structure superpositions and distance calculations were performed in Pymol. The cryo-EM maps for Structure I and II were deposited in the EMDB (EMD-8522 and EMD-8521, respectively) (RRID:[SCR_006506](https://scicrunch.org/resolver/SCR_006506)). PDB coordinates for Structures I and II were deposited in the RCSB (PDB codes 5U9G and 5U9F, respectively) (RRID:[SCR_012820](https://scicrunch.org/resolver/SCR_012820)). Figures were prepared in Pymol and Chimera ([@bib15]; [@bib45]).

Sequence and structural analysis {#s3-6}
--------------------------------

NCBI (PSI) BLAST (RRID:[SCR_004870](https://scicrunch.org/resolver/SCR_004870)) ([@bib3]) was used to obtain \~400 non-redundant ArfA homolog sequences with less than 95% identity to that of *E. coli* ArfA. MUSCLE (RRID:[SCR_011812](https://scicrunch.org/resolver/SCR_011812)) ([@bib16]) was used to generate a multiple-sequence alignment which was presented with WebLogo 3 (RRID:[SCR_010236](https://scicrunch.org/resolver/SCR_010236)) ([@bib14]) ([Figure 2](#fig2){ref-type="fig"}).
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Thank you for submitting your article \"Mechanism of ribosome rescue by ArfA and RF2\" for consideration by *eLife*. Your article has been favorably evaluated by John Kuriyan (Senior Editor) and three reviewers, one of whom, Rachel Green (Reviewer \#1), is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal their identity: Venki Ramakrishnan (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We have received comments from the reviewers and all three support the publication of this manuscript in *eLife* pending revisions. The reviewers all appreciate that there is new information on ArfA and RF2 binding to the ribosome, even in light of recent publications on this same topic from multiple groups. However, this study will need to be better placed within that (new) context, in particular addressing the key question as to why the alternative compact conformation was so readily observed in this sample, even though a wild type ArfA protein was utilized. We look forward to receiving a revised submission addressing these points raised by the reviewers.

*Reviewer \#1:*

This manuscript describes two structures of ArfA and RF2 bound to bacterial ribosomes, in two distinct states, one likely active to promote peptide and the other in a state either that precedes or follows peptide release. The manuscript clearly describes distinct features of these structures relative to previously described structures of related systems (RF2 on stop codon programmed ribosomes and to a lesser extent SmpB and ArfB bound ribosomes) and attempts to reconcile the structures with previous mutational analyses. Despite the recent publications from competitors in Nature and Science, this manuscript still has merit in particular because it presents these two different structures that (almost certainly) reveal something about relevant intermediates in this rescue pathway. Of course, these papers now published will need to be cited and comparisons to them made in a revised manuscript. Overall, I find the manuscript suitable for publication and hope that the authors will address several specific points below:

1\) References to ArfA in \"pathogenic bacteria\" seems gratuitous and not informative -- I would eliminate this (Introduction, first paragraph).

2\) [Figure 1](#fig1){ref-type="fig"} -- panels A and B -- ArfA not red enough to look different in color from orange P site tRNA -- distinction better in subsequent panels.

3\) The discussion of commonalities with ArfB and SmpB could be extended and some of the biochemistry on this topic alluded to (the role for an extended α helix on SmpB, for example, could be discussed).

4\) At the risk of being self-serving, work from my group from 2010 (<https://www.ncbi.nlm.nih.gov/pubmed/20208546>) documented conformational changes in the positioning of RF1 on ribosomes as a result of cognate (relative to near-cognate) stop codon recognition (using tethered BABE probing). I wonder if it might be interesting to compare some of these structural events by admittedly a lower resolution study to the current \"induced\" state seen here by cryoEM.

*Reviewer \#2:*

This is an important paper that describes an alternate rescue system in bacteria for ribosomes that are stalled on an mRNA without a stop codon. It involves a protein, ArfA, that binds to the A site of the ribosome in the absence of message in the A site, and recruits release factor RF2. Binding induces a conformational change that results in the active form of RF2 that cleaves the nascent peptide. The authors have used cryoEM to capture both the initial inactive state as well as the final activated state from the same sample.

1\) Since this paper was submitted, three other structures of similar complexes have been published. Therefore, the paper could be improved by analyzing it in the light of these other results without really detracting from the authors\' credit (their BioRxiv preprint clearly establishes their work was independent and nearly simultaneous). For example, the compact inactive RF2 conformation is no longer \"hitherto unobserved\" but has now also been reported by James et al. in Science.

2\) The two observed states determined from a single sample are puzzling. The recent structures of wild-type ArfA with wild-type RF2 from Huter et al., James et al. and Ma et al. only report a single conformation. It seems unlikely that the difference is due to different EM processing schemes as the compact class in this manuscript is not a minor species, but is even more prevalent than the extended class.

James et al. were able to observe the compact conformation, but only by using an ArfA mutant or a heterologous release factor from *Thermus thermophilus*. Mutations in the N-terminus of ArfA or the switch loop of RF2 could potentially cause the observed compact conformation and it may be that the authors have a mixture of wild-type and mutant ArfA.

If there is no mutant protein in the sample, why do the authors think they observe both conformations? Are there substantial differences in the way in which the complex is formed compared to Huter et al., James et al. and Ma et al? Could the uncleaved histidine-tag at the N-terminus of ArfA interfere with complex formation?

3\) The authors propose a mechanism and video ([Figure 5](#fig5){ref-type="fig"}) from their observed states in which Structure I binds prior to a transition to Structure II. In my opinion the authors are probably correct, but there is some evidence that the release factor exists in two states in solution as shown by one SAXS study (Zoldak et al. 2007. NAR) so the binding of both forms could be independent. Alternatively, the compact conformation may occur after peptide-bond cleavage. Do the authors observe density for the fMet group in both conformations to confirm that both conformations occur prior to peptide bond cleavage? This may be worth discussing.

*Reviewer \#3:*

This manuscript describes two cryo-EM structures of ArfA- and RF2-bound ribosomes stalled on a truncated mRNA at 3.2-Å resolution. The two structures, isolated from the same sample, reveal two distinct conformations of RF2, providing information on the structural dynamics of ribosome-bound RF2 during ArfA-mediated ribosome rescue. The work described here clearly advances our understanding of the ArfA-mediated ribosome rescue pathway and we therefore recommend publication of this manuscript in *eLife*.

10.7554/eLife.23687.026

Author response

*\[...\] Reviewer \#1:*

*\[...\] 1) References to ArfA in \"pathogenic bacteria\" seems gratuitous and not informative -- I would eliminate this (Introduction, first paragraph).*

We eliminated this sentence.

*2) [Figure 1](#fig1){ref-type="fig"} -- panels A and B -- ArfA not red enough to look different in color from orange P site tRNA -- distinction better in subsequent panels.*

We improved panels A and B in [Figure 1](#fig1){ref-type="fig"} to make ArfA red and distinct from orange of the P-site tRNA.

*3) The discussion of commonalities with ArfB and SmpB could be extended and some of the biochemistry on this topic alluded to (the role for an extended α helix on SmpB, for example, could be discussed).*

We have extended the Discussion and provide a paragraph on commonalities and differences among ArfA, ArfB and SmpB, including the role of an extended α-helix.

*4) At the risk of being self-serving, work from my group from 2010 (<https://www.ncbi.nlm.nih.gov/pubmed/20208546>) documented conformational changes in the positioning of RF1 on ribosomes as a result of cognate (relative to near-cognate) stop codon recognition (using tethered BABE probing). I wonder if it might be interesting to compare some of these structural events by admittedly a lower resolution study to the current \"induced\" state seen here by cryoEM.*

We thank the reviewer for pointing this out. We now draw a parallel with stop-codon decoding and provide references to the BABE-probing work by the Green lab and fluorescence-based work by the Simpson lab, which showed conformational rearrangements in release factors.

*Reviewer \#2:*

*\[...\] 1) Since this paper was submitted, three other structures of similar complexes have been published.Therefore, the paper could be improved by analyzing it in the light of these other results without really detracting from the authors\' credit (their BioRxiv preprint clearly establishes their work was independent and nearly simultaneous). For example, the compact inactive RF2 conformation is no longer \"hitherto unobserved\" but has now also been reported by James et al. in Science.*

We have included a discussion of the papers published since the submission of our manuscript.

We have eliminated the expression "hitherto unobserved".

*2) The two observed states determined from a single sample are puzzling. The recent structures of wild-type ArfA with wild-type RF2 from Huter et al., James et al. and Ma et al. only report a single conformation. It seems unlikely that the difference is due to different EM processing schemes as the compact class in this manuscript is not a minor species, but is even more prevalent than the extended class.*

*James et al. were able to observe the compact conformation, but only by using an ArfA mutant or a heterologous release factor from Thermus thermophilus. Mutations in the N-terminus of ArfA or the switch loop of RF2 could potentially cause the observed compact conformation and it may be that the authors have a mixture of wild-type and mutant ArfA.*

*If there is no mutant protein in the sample, why do the authors think they observe both conformations? Are there substantial differences in the way in which the complex is formed compared to Huter et al., James et al. and Ma et al? Could the uncleaved histidine-tag at the N-terminus of ArfA interfere with complex formation?*

We discuss several factors that may have contributed to the difference of our work from the other reports. Our observation of both conformations is not due to an ArfA mutant, as we state in Methods that "DNA sequencing confirmed the native sequence of the ArfA gene". Furthermore, we confirmed the enzymatic activity of ArfA (see Methods). Among the likely factors are: (1) Different data processing in our work employing Frealign. This approach also resulted in more than one conformation in our recently published studies of RelA (Loveland et al., 2016) and IRES mRNA (Abeyrathne et al., 2016), unlike the concurrent reports of similar complexes from other labs that used Relion or other strategies and reported a single state in each report (Fernandes et al., *eLife*, 2016; Brown et al., 2016; Arenz et al., 2016). (2) Use of the His6-tag on ArfA. This may have contributed to stabilization of the less abundant Structure I, however we do not observe the His-tag and its potential interactions in cryo-EM maps. We note that Huter et al. had an extension on ArfA resulting from protease cleavage, which did not result in observation of Structure I in their work. (3) Different buffer composition and 70S complex assembly. We assembled the complexes using individual ribosome subunits (purified from endogenous tRNAs and mRNA). Also, buffer conditions, with different concentrations of Mg or other ions could have an effect on the equilibrium between states I and II.

*3) The authors propose a mechanism and video ([Figure 5](#fig5){ref-type="fig"}) from their observed states in which Structure I binds prior to a transition to Structure II. In my opinion the authors are probably correct, but there is some evidence that the release factor exists in two states in solution as shown by one SAXS study (Zoldak et al. 2007. NAR) so the binding of both forms could be independent. Alternatively, the compact conformation may occur after peptide-bond cleavage. Do the authors observe density for the fMet group in both conformations to confirm that both conformations occur prior to peptide bond cleavage? This may be worth discussing.*

There is indeed a discussion in the field that RFs exist in solution in both the closed and open forms. Recent studies, however, converge to a view that RFs are predominantly compact (Zoldak et al., 2007; Trappl and Joseph, 2016) and that the initial SAXS report may have overestimated the degree of RF1 opening. We have extended our Discussion to address this point of the reviewer.

As for fMet, we used deacylated tRNA^fMet^ as we state in Methods, and we do not observe density for fMet in the PTC, as expected.

[^1]: Medicago, Durham, United States.
